Info and article are below this top vid by Tim Pool
The hype was real. The announcement landed this week, and the markets noticed immediately. Moderna and Merck reported that their experimental personalized mRNA cancer vaccine, intismeran autogene (also known as mRNA-4157 or V940), met its key goals in a large Phase 3 trial for high-risk melanoma. Patients who received the custom vaccine plus Merck’s Keytruda stayed free of recurrence longer and saw less spread of the disease than those who got Keytruda alone.
This is the first successful late-stage trial for an mRNA-based cancer vaccine and the first clear Phase 3 win for a fully individualized neoantigen therapy. After years of promise, the technology that powered the COVID shots is now showing real muscle against one of the deadliest forms of skin cancer.
How the Vaccine Works
Doctors sequence the patient’s tumor after surgical removal and identify unique mutations (neoantigens) that distinguish the cancer cells from healthy ones. Moderna’s platform then builds a custom mRNA shot encoding up to 34 of those mutations. Once injected, the patient’s cells produce copies of those tumor “fingerprints,” training the immune system to hunt down any remaining cancer cells. The vaccine is given alongside Keytruda, which releases the brakes on the immune response. The whole process from tumor sample to ready vaccine takes roughly six weeks.
This is not a one-size-fits-all shot. It is built for the individual patient’s cancer.
The Trial Results
The Phase 3 trial (INTerpath-001) enrolled 1,137 patients with completely resected stage IIB–IV cutaneous melanoma—patients at high risk of the cancer returning. They were randomized to receive either the personalized vaccine plus Keytruda or Keytruda alone for about a year. At a planned interim analysis, the combination delivered statistically significant and clinically meaningful improvements in both recurrence-free survival (the primary endpoint) and distant metastasis-free survival.
Exact percentages from the Phase 3 data have not yet been released in full; the companies plan to present detailed results at an upcoming medical meeting. Earlier Phase 2 data (KEYNOTE-942) showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% at five years of follow-up. Those durable numbers helped build confidence heading into the larger trial.
Moderna shares more than doubled on the news. Merck climbed as well. Company executives called the result a landmark and said they are already talking with regulators. Availability could come as early as 2027 if the full data hold up and approval moves quickly.
Which Cancers Does It Target?
Right now the strongest data are in high-risk melanoma after surgery. That is the cancer that just cleared Phase 3.
The same personalized platform is already in trials for other solid tumors:
- Non-small cell lung cancer (multiple Phase 3 trials in the adjuvant and related settings)
- Bladder cancer (high-risk muscle-invasive and non-muscle-invasive)
- Renal cell carcinoma (the most common form of kidney cancer)
- Earlier-stage work in pancreatic and stomach/gastric cancers
Moderna and Merck have repeatedly said results from several of these studies are expected over the next one to two years. Rival programs from other companies are also testing similar neoantigen approaches in colorectal and pancreatic cancer. The melanoma success provides proof-of-concept that the strategy can work and can be designed against many different tumor types.
Moderna and Merck said a personalized mRNA cancer vaccine reduced the risk of melanoma recurrence and spread in a late-stage trial, sending Moderna shares soaring as much as 160% https://t.co/SIp2qBzOUY pic.twitter.com/Iedu0xQBnN
— Reuters (@Reuters) August 20, 2026
Why This Matters
Cancer vaccines have been the holy grail for decades. Most earlier attempts failed. This one is different because it is truly individualized and uses the flexible, rapid-manufacturing power of mRNA. For the thousands of Americans diagnosed with high-risk melanoma every year, a treatment that meaningfully cuts the chance of the cancer coming back after surgery is a genuine advance. Quite a few of us here at Whatfinger have zero trust in anything that is mRNA as it has genetic components and trusting Big Pharma is not high on our list after Covid. But since this for individuals and based on your own cancer, there are possibilities.
It is also a reminder of what American private-sector science can still deliver when it focuses on hard problems instead of political theater. Moderna, a Cambridge, Massachusetts company, and Merck, a long-time U.S. pharmaceutical powerhouse, just put real data on the board against a killer disease. Full peer-reviewed numbers and long-term survival data still need to come. Regulators will demand a careful look. But the direction of travel is clear: personalized mRNA cancer therapy is no longer science fiction.
For patients and families staring down a melanoma diagnosis, this week’s news is the best kind of development—hope backed by a successful late-stage trial.
—The Whatfinger News Team: Sgt K and Lisa
Resources
- Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments? | Nature
- Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope | Reuters
- mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say – Ars Technica
- Novel Moderna-Merck Cancer Vaccine Prevents Melanoma From Returning in First for mRNA – WSJ
- Moderna, Merck breakthrough could usher in wave of cancer vaccines | Reuters
- Moderna’s cancer vaccine trials could pave way for shift in care – Boston Globe
- Personalized mRNA-Based Melanoma Vaccine Meets Primary Endpoints in Landmark Phase 3 Trial | Dermatology Times
- A New Milestone in Melanoma: Personalized mRNA-Based Cancer Therapy Shows Positive Phase 3 Results – Melanoma Research Alliance
- He just did it, it happened (The hype on a Moderna vaccine against Cancer) – Dedicated Issues
Top Features and Vids across all Whatfinger sites right now
- Alex Jones GOES FULL DEEP STATE, Demands Bareknuckle Fight With | Tim Pool Vid
- Toka’s “Frictionless Surveillance”: Israeli Firm Sells Access to Any Internet Camera—Including Your Ring—and the Power to Rewrite Reality for Profit
- Americans walks from scale to scale and shows the amount of meat is under 1 pound… but it’s marked and sold as 2 pounds This is fraud
- TREASON IN PLAIN SIGHT: Democrats Kept CCP Honeytrap Asset Eric Swalwell on the House Intelligence Committee After the FBI Warned Them
Get on over to Whatfinger.com – Whatfinger News does millions of pageviews a month for a reason…. Truth, Justice, the American way, plus news on the Left as well – all links from all sites gives you the true news. – CLICK HERE 🛑
Drudge Report Alternative
This one is dark…. After the Democrats steal both Houses in November…
